Journal of Thrombosis and Thrombolysis

, Volume 42, Issue 2, pp 161–166 | Cite as

Dabigatran and rivaroxaban do not affect AA- and ADP-induced platelet aggregation in patients receiving concomitant platelet inhibitors

  • Christoph B. Olivier
  • Patrick Weik
  • Melanie Meyer
  • Susanne Weber
  • Philipp Diehl
  • Christoph Bode
  • Martin Moser
  • Qian Zhou
Article
First Online:

Abstract

Dabigatran and rivaroxaban are novel, vitamin K-independent oral anticoagulants (NOACs) and act via antagonism of the coagulation factor (F) IIa (dabigatran) or FXa (rivaroxaban), respectively. Compared to vitamin-K-antagonists, NOACs have shown non-inferiority of risk and benefit in patients with non valvular atrial fibrillation (AF). In clinical practice there is increasing use of NOACs combined with platelet inhibitors in patients with AF and coronary artery disease. However, whether NOACs affect the function of platelet inhibitors remains incompletely known. This observational study aimed to assess the platelet function in patients receiving dabigatran or rivaroxaban and concomitant platelet inhibitors. A single centre observational study was performed analysing the platelet aggregation of patients treated with dabigatran or rivaroxaban with or without concomitant platelet inhibitors. Measurements before the initiation of NOAC therapy served as the respective control group. Platelet aggregation was measured by multiple electrode aggregometry and was induced with adenosine diphosphate (ADP, 6.5 µM) and arachidonic acid (AA, 0.5 mM), respectively. In order to evaluate whether NOACs interact with platelet inhibition by ASA or the P2Y12-antagonist clopidogrel, 87 patients were grouped according to their concomitant antiplatelet medication. Comparing the ADP- and AA-induced platelet aggregation in patients without concomitant platelet inhibitors (n = 45) no significant differences under therapy with dabigatran (d) or rivaroxaban (r) compared to the control group (c) were observed. In patients taking clopidogrel as a concomitant platelet inhibitor (n = 21), neither dabigatran nor rivaroxaban affected the ADP-induced platelet aggregation (c 20 ± 11, d 21 ± 14, r 18 ± 8 AU*min, p = 0.200). Patients receiving dabigatran or rivaroxaban in combination with ASA (n = 42; 21 ASA only, 21 ASA + clopidogrel) showed no significant differences of the AA-induced aggregation compared to the control group (c 10 ± 8, d 9 ± 7, r 10 ± 8 AU*min, p = 0.810). The antiplatelet effects of ASA and clopidogrel monitored by AA- or ADP-induced platelet aggregation were not affected by NOAC therapy.

Keywords

Dabigatran Rivaroxaban ASA Clopidogrel 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgments

This work was supported by a grant from the Deutsche Forschungsgemeinschaft (OL 371/1–1 to Christoph B. Olivier).

Compliance with ethical standards

Conflict of interest

C Olivier, P. Diehl, Q. Zhou and M. Moser are investigators in PIONEER AF-PCI. P. Diehl received speaker’s fees from Lilly Deutschland GmbH. C. Bode received speaker’s fees from Merck, AstraZeneca, Sanofi und Bayer. M. Moser received speaker’s fees from Bayer Vital GmbH, AstraZeneca GmbH, Daiichi Sankyo Deutschland GmbH, Pfizer/Bristol-Myers Squibb, Berlin Chemie AG, Lilly Deutschland GmbH, Boehringer Ingelheim Pharma GmbH & Co. and KG Sanofi-Aventis Deutschland GmbH.

References

  1. 1.
    Ajjan R, Grant PJ (2006) Coagulation and atherothrombotic disease. Atherosclerosis 186:240–259CrossRefPubMedGoogle Scholar
  2. 2.
    Walsh PN (2004) Platelet coagulation-protein interactions. Semin Thromb Hemost 30:461–471CrossRefPubMedGoogle Scholar
  3. 3.
    Hoffman M (2003) Remodeling the blood coagulation cascade. J Thromb Thrombolysis 16:17–20CrossRefPubMedGoogle Scholar
  4. 4.
    Borissoff JI, Spronk HM, ten Cate H (2011) The hemostatic system as a modulator of atherosclerosis. N Engl J Med 364:1746–1760CrossRefPubMedGoogle Scholar
  5. 5.
    Crawley JT, Zanardelli S, Chion CK, Lane DA (2007) The central role of thrombin in hemostasis. J Thromb Haemost 5(Suppl 1):95–101CrossRefPubMedGoogle Scholar
  6. 6.
    Olivier C, Diehl P, Bode C, Moser M (2013) Thrombin receptor antagonism in antiplatelet therapy. Cardiol Ther 2:57–68CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Coughlin SR (2005) Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost 3:1800–1814CrossRefPubMedGoogle Scholar
  8. 8.
    Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981–992CrossRefPubMedGoogle Scholar
  9. 9.
    Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–1151CrossRefPubMedGoogle Scholar
  10. 10.
    Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883–891CrossRefPubMedGoogle Scholar
  11. 11.
    Moser M, Olivier CB, Bode C (2014) Triple antithrombotic therapy in cardiac patients: more questions than answers. Eur Heart J 35:216–223CrossRefPubMedGoogle Scholar
  12. 12.
    Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL et al (2012) Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 366:9–19CrossRefPubMedGoogle Scholar
  13. 13.
    Alexander JH, Lopes RD, James S, Kilaru R, He Y et al (2011) Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 365:699–708CrossRefPubMedGoogle Scholar
  14. 14.
    Olivier CB, Weik P, Meyer M, Weber S, Anto-Michel N et al (2015) TRAP-induced platelet aggregation is enhanced in cardiovascular patients receiving dabigatran. Thromb Res 138:63–68CrossRefPubMedGoogle Scholar
  15. 15.
    Olivier CB, Schnabel K, Weber S, Zhou Q, Bode C et al (2016) Platelet reactivity after administration of third generation P2Y-antagonists does not depend on body weight in contrast to clopidogrel. J Thromb Thrombolysis. doi: 10.1007/s11239-016-1340-9 Google Scholar
  16. 16.
    Gornbein JA, Lazaro CG, Little RJ (1992) Incomplete data in repeated measures analysis. Stat Methods Med Res 1:275–295CrossRefPubMedGoogle Scholar
  17. 17.
    Perzborn E, Heitmeier S, Buetehorn U, Laux V (2014) Direct thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor-induced hypercoagulability in vitro and in vivo. J Thromb Haemost 12:1054–1065CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Martischnig AM, Mehilli J, Pollak J, Petzold T, Fiedler AK et al (2015) Impact of dabigatran versus phenprocoumon on ADP induced platelet aggregation in patients with atrial fibrillation with or without concomitant clopidogrel therapy (the Dabi-ADP-1 and Dabi-ADP-2 Trials). Biomed Res Int 2015:798486CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Kuliczkowski W, Witkowski A, Polonski L, Watala C, Filipiak K et al (2009) Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J 30:426–435CrossRefPubMedGoogle Scholar
  20. 20.
    Zemer-Wassercug N, Haim M, Leshem-Lev D, Orvin KL, Vaduganathan M et al (2015) The effect of dabigatran and rivaroxaban on platelet reactivity and inflammatory markers. J Thromb Thrombolysis 40:340–346CrossRefPubMedGoogle Scholar
  21. 21.
    Eller T, Busse J, Dittrich M, Flieder T, Alban S et al (2014) Dabigatran, rivaroxaban, apixaban, argatroban and fondaparinux and their effects on coagulation POC and platelet function tests. Clin Chem Lab Med 52:835–844CrossRefPubMedGoogle Scholar
  22. 22.
    Weisshaar S, Litschauer B, Gouya G, Mayer P, Smerda L et al (2014) Antithrombotic triple therapy and coagulation activation at the site of thrombus formation: a randomized trial in healthy subjects. J Thromb Haemost 12:1850–1860CrossRefPubMedGoogle Scholar
  23. 23.
    Oldgren J, Budaj A, Granger CB, Khder Y, Roberts J et al (2011) Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J 32:2781–2789CrossRefPubMedGoogle Scholar
  24. 24.
    Gibson CM, Mehran R, Bode C, Halperin J, Verheugt F et al (2015) An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). Am Heart J 169(472–478):e475Google Scholar
  25. 25.
    Yamamoto J, Inoue N, Otsui K, Ishii H, Gorog DA (2014) Global Thrombosis Test (GTT) can detect major determinants of haemostasis including platelet reactivity, endogenous fibrinolytic and thrombin generating potential. Thromb Res 133:919–926CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.Cardiology and Angiology I, Heart CenterFreiburg UniversityFreiburg - Bad KrozingenGermany
  2. 2.Center for Medical Biometry and Medical InformaticsMedical Center - University of FreiburgFreiburgGermany

Personalised recommendations